Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicorette spray among proposed U.K. switches

This article was originally published in The Tan Sheet

Executive Summary

The U.K. health authority considers applications to switch McNeil Products' Nicorette Nasal Spray smoking-cessation product from pharmacy to general sales status. In addition to the application from the Johnson & Johnson division operating in the U.K., the Medicines and Healthcare products Regulatory Agency seeks comments on P-to-GSL switch applications from Thornton & Rose for Hedrin Lotion (dimecticone) indicated for lice, and from Diomed Developments for Bazuka Treatment Gel (salicylic and lactic acids) for warts, verrucas, corns and calluses, and for Freederm Gel PL (nicotinamide) acne treatment. McNeil Products says since nicotine-replacement therapy patches, gum, lozenges and tablets already are available GSL in the U.K., the spray should be also. The firm says the 0.5 mg per-spray dose of the product is less than the maximum dose allowed for NRT products currently available GSL. Comments on each U.K. application are due by Oct. 29. In the U.S., NRT gum, lozenges and patches are available OTC, but not spray, according to FDA
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS102194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel